Literature DB >> 26699912

Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.

Magdalena Korczynska, Daniel D Le, Noah Younger, Elisabet Gregori-Puigjané, Anthony Tumber1,2, Tobias Krojer1, Srikannathasan Velupillai1, Carina Gileadi1, Radosław P Nowak1, Eriko Iwasa, Samuel B Pollock, Idelisse Ortiz Torres, Udo Oppermann1,3, Brian K Shoichet, Danica Galonić Fujimori.   

Abstract

Development of tool molecules that inhibit Jumonji demethylases allows for the investigation of cancer-associated transcription. While scaffolds such as 2,4-pyridinedicarboxylic acid (2,4-PDCA) are potent inhibitors, they exhibit limited selectivity. To discover new inhibitors for the KDM4 demethylases, enzymes overexpressed in several cancers, we docked a library of 600,000 fragments into the high-resolution structure of KDM4A. Among the most interesting chemotypes were the 5-aminosalicylates, which docked in two distinct but overlapping orientations. Docking poses informed the design of covalently linked fragment compounds, which were further derivatized. This combined approach improved affinity by ∼ 3 log-orders to yield compound 35 (Ki = 43 nM). Several hybrid inhibitors were selective for KDM4C over the related enzymes FIH, KDM2A, and KDM6B while lacking selectivity against the KDM3 and KDM5 subfamilies. Cocrystal structures corroborated the docking predictions. This study extends the use of structure-based docking from fragment discovery to fragment linking optimization, yielding novel KDM4 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26699912      PMCID: PMC5080985          DOI: 10.1021/acs.jmedchem.5b01527

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  74 in total

1.  Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4.

Authors:  Michael M Mysinger; Dahlia R Weiss; Joshua J Ziarek; Stéphanie Gravel; Allison K Doak; Joel Karpiak; Nikolaus Heveker; Brian K Shoichet; Brian F Volkman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

2.  Rapid context-dependent ligand desolvation in molecular docking.

Authors:  Michael M Mysinger; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2010-09-27       Impact factor: 4.956

Review 3.  Screening in a spirit haunted world.

Authors:  Brian K Shoichet
Journal:  Drug Discov Today       Date:  2006-07       Impact factor: 7.851

4.  Histone demethylation by a family of JmjC domain-containing proteins.

Authors:  Yu-ichi Tsukada; Jia Fang; Hediye Erdjument-Bromage; Maria E Warren; Christoph H Borchers; Paul Tempst; Yi Zhang
Journal:  Nature       Date:  2005-12-18       Impact factor: 49.962

5.  Development of homogeneous luminescence assays for histone demethylase catalysis and binding.

Authors:  Akane Kawamura; Anthony Tumber; Nathan R Rose; Oliver N F King; Michelle Daniel; Udo Oppermann; Tom D Heightman; Christopher Schofield
Journal:  Anal Biochem       Date:  2010-05-21       Impact factor: 3.365

6.  The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.

Authors:  Jun Yang; Adrian M Jubb; Luke Pike; Francesca M Buffa; Helen Turley; Dilair Baban; Russell Leek; Kevin C Gatter; Jiannis Ragoussis; Adrian L Harris
Journal:  Cancer Res       Date:  2010-08-03       Impact factor: 12.701

7.  Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.

Authors:  Baptiste Villemagne; Marion Flipo; Nicolas Blondiaux; Céline Crauste; Sandra Malaquin; Florence Leroux; Catherine Piveteau; Vincent Villeret; Priscille Brodin; Bruno O Villoutreix; Olivier Sperandio; Sameh H Soror; Alexandre Wohlkönig; René Wintjens; Benoit Deprez; Alain R Baulard; Nicolas Willand
Journal:  J Med Chem       Date:  2014-05-28       Impact factor: 7.446

8.  Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.

Authors:  Sook Shin; Ralf Janknecht
Journal:  Biochem Biophys Res Commun       Date:  2007-06-04       Impact factor: 3.575

9.  5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation.

Authors:  Richard J Hopkinson; Anthony Tumber; Clarence Yapp; Rasheduzzaman Chowdhury; WeiShen Aik; Ka Hing Che; Xuan Shirley Li; Jan B L Kristensen; Oliver N F King; Mun Chiang Chan; Kar Kheng Yeoh; Hwanho Choi; Louise J Walport; Cyrille C Thinnes; Jacob T Bush; Clarisse Lejeune; Anna M Rydzik; Nathan R Rose; Eleanor A Bagg; Michael A McDonough; Tobias Krojer; Wyatt W Yue; Stanley S Ng; Lars Olsen; Paul E Brennan; Udo Oppermann; Susanne Muller-Knapp; Robert J Klose; Peter J Ratcliffe; Christopher J Schofield; Akane Kawamura
Journal:  Chem Sci       Date:  2013-08-01       Impact factor: 9.825

10.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

View more
  13 in total

Review 1.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

2.  In Silico Discovery of JMJD6 Inhibitors for Cancer Treatment.

Authors:  Ting Ran; Rongquan Xiao; Qixuan Huang; Haoliang Yuan; Tao Lu; Wen Liu
Journal:  ACS Med Chem Lett       Date:  2019-11-19       Impact factor: 4.345

Review 3.  Twenty years on: the impact of fragments on drug discovery.

Authors:  Daniel A Erlanson; Stephen W Fesik; Roderick E Hubbard; Wolfgang Jahnke; Harren Jhoti
Journal:  Nat Rev Drug Discov       Date:  2016-07-15       Impact factor: 84.694

4.  Computational Prediction of the Binding Pose of Metal-Binding Pharmacophores.

Authors:  Johannes Karges; Ryjul W Stokes; Seth M Cohen
Journal:  ACS Med Chem Lett       Date:  2022-02-24       Impact factor: 4.345

Review 5.  Recent Advances with KDM4 Inhibitors and Potential Applications.

Authors:  Qiong Wu; Brandon Young; Yan Wang; Andrew M Davidoff; Zoran Rankovic; Jun Yang
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039

Review 6.  Computer-Aided Drug Design in Epigenetics.

Authors:  Wenchao Lu; Rukang Zhang; Hao Jiang; Huimin Zhang; Cheng Luo
Journal:  Front Chem       Date:  2018-03-12       Impact factor: 5.221

7.  Small molecule KDM4s inhibitors as anti-cancer agents.

Authors:  Hongzhi Lin; Qihang Li; Qi Li; Jie Zhu; Kai Gu; Xueyang Jiang; Qianqian Hu; Feng Feng; Wei Qu; Yao Chen; Haopeng Sun
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

8.  Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.

Authors:  Piotr H Małecki; Nicole Rüger; Martin Roatsch; Oxana Krylova; Andreas Link; Manfred Jung; Udo Heinemann; Manfred S Weiss
Journal:  ChemMedChem       Date:  2019-10-10       Impact factor: 3.466

Review 9.  The emerging role of KDM5A in human cancer.

Authors:  Guan-Jun Yang; Ming-Hui Zhu; Xin-Jiang Lu; Yan-Jun Liu; Jian-Fei Lu; Chung-Hang Leung; Dik-Lung Ma; Jiong Chen
Journal:  J Hematol Oncol       Date:  2021-02-17       Impact factor: 17.388

10.  Synthesis and Demonstration of the Biological Relevance of sp3 -rich Scaffolds Distantly Related to Natural Product Frameworks.

Authors:  Daniel J Foley; Philip G E Craven; Patrick M Collins; Richard G Doveston; Anthony Aimon; Romain Talon; Ian Churcher; Frank von Delft; Stephen P Marsden; Adam Nelson
Journal:  Chemistry       Date:  2017-10-06       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.